2507 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011
22 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
23 Recruiting Phenylbutyrate As a Treatment for Abnormal Accumulation of Brain Protein in Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Glycerol Phenylbutyrate
24 Not yet recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
25 Not yet recruiting Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Biological: nivolumab;   Other: laboratory biomarker analysis
26 Recruiting Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
27 Completed Analysis of the Enteric Nervous System Using Colonic Biopsies
Conditions: Parkinson's Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention: Procedure: colonoscopy or rectosigmoidoscopy
28 Recruiting PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Interventions: Biological: Nivolumab;   Drug: Ipilimumab
29 Active, not recruiting Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Condition: Cancer, Solid Tumor
Interventions: Drug: Pembrolizumab 1 mg/kg;   Drug: Pembrolizumab 3 mg/kg;   Drug: Pembrolizumab 10 mg/kg;   Drug: Pembrolizumab MEL;   Drug: Pembrolizumab NSCLC;   Drug: Pembrolizumab MEL Low Dose;   Drug: Pembrolizumab MEL High Dose;   Drug: Pembrolizumab NSCLC Low Dose;   Drug: Pembrolizumab NSCLC High Dose;   Drug: Pembrolizumab NSCLC Medium Dose
30 Unknown  Diagnostic and Prognostic Biomarkers in Parkinson Disease
Conditions: Parkinson Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Intervention:
31 Completed
Has Results
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
Conditions: Psoriasis;   Immunomodulation
Intervention: Drug: tofacitinib
32 Recruiting Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.
Condition: Non-Small Lung Cancer, Epigenetic Therapy
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Drug: CC-486
33 Terminated Early Parkinson's Disease (PD) Cross-Sectional
Condition: Parkinson's Disease
Intervention:
34 Not yet recruiting Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: pembrolizumab;   Other: laboratory biomarker analysis
35 Recruiting Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IIB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions: Biological: pembrolizumab;   Other: laboratory biomarker analysis
36 Recruiting A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Condition: Non-small Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Drug: Pemetrexed;   Biological: Ipilimumab;   Drug: Erlotinib;   Drug: Gefitinib
37 Recruiting Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Pembrolizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Gemcitabine
38 Not yet recruiting Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC)
Intervention: Biological: pembrolizumab
39 Recruiting Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease
Conditions: HIV;   Smoking;   COPD
Intervention:
40 Active, not recruiting Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)
Condition: Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Ipilimumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years